Search

Search results

1498 results found

Danon Disease-Associated LAMP-2 Deficiency Drives Metabolic Signature Indicative of Mitochondrial Aging and Fibrosis in Cardiac Tissue and hiPSC-Derived Cardiomyocytes.

Publication: Journal Article

Del Favero, Giorgia, Alois Bonifacio, Teisha J Rowland, Shanshan Gao, Kunhua Song, Valter Sergo, Eric D Adler, Luisa Mestroni, Orfeo Sbaizero, and Matthew R G Taylor. 2020. “Danon Disease-Associated LAMP-2 Deficiency Drives Metabolic Signature Indicative of Mitochondrial Aging and Fibrosis in Cardiac Tissue and HiPSC-Derived Cardiomyocytes.”. Journal of Clinical Medicine 9 (8).

Deubiquitylase USP9X maintains centriolar satellite integrity by stabilizing pericentriolar material 1 protein.

Publication: Journal Article

Han, Ke-Jun, Zhiping Wu, Chad G Pearson, Junmin Peng, Kunhua Song, and Chang-Wei Liu. 2019. “Deubiquitylase USP9X Maintains Centriolar Satellite Integrity by Stabilizing Pericentriolar Material 1 Protein.”. Journal of Cell Science 132 (2).

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes.

Publication: Journal Article

Riching, Andrew S, Yuanbiao Zhao, Yingqiong Cao, Pilar Londono, Hongyan Xu, and Kunhua Song. 2018. “Suppression of Pro-Fibrotic Signaling Potentiates Factor-Mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes.”. Journal of Visualized Experiments : JoVE, no. 136.

ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression.

Publication: Journal Article

Zhou, Huanyu, Maria Gabriela Morales, Hisayuki Hashimoto, Matthew E Dickson, Kunhua Song, Wenduo Ye, Min S Kim, et al. 2017. “ZNF281 Enhances Cardiac Reprogramming by Modulating Cardiac and Inflammatory Gene Expression.”. Genes & Development 31 (17): 1770-83.

High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling.

Publication: Journal Article

Zhao, Yuanbiao, Pilar Londono, Yingqiong Cao, Emily J Sharpe, Catherine Proenza, Rebecca O’Rourke, Kenneth L Jones, et al. 2015. “High-Efficiency Reprogramming of Fibroblasts into Cardiomyocytes Requires Suppression of Pro-Fibrotic Signalling.”. Nature Communications 6: 8243.

Truman Roland

Person: PhD student

I am a graduate student pursuing a PhD in medical sciences at the Morsani College of Medicine (MCOM)). I earned my B.S. in biomedical engineering from USF in 2023 where I specialized in tissue engineering and wound healing. Now, I apply these tissue engineering techniques to the regeneration of the...

Novel Gottingen miniswine model of heart failure with preserved ejection fraction integrating multiple comorbidities

Publication: Journal Article

Sharp, TE., A. Scarborough, Z. Li, DJ. Polhemus, H. Hidalgo, JD. Schumacher, TR. Matsuura, et al. 2022. “Novel Gottingen Miniswine Model of Heart Failure With Preserved Ejection Fraction Integrating Multiple Comorbidities”. JACC: Basic to Translational Science.

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. 2023 Jul 7;9:100212. doi: 10.1016/j.prdoa.2023.100212. eCollection 2023. PMID: 37497384

Publication: Journal Article

Isaacson, SH, RA Hauser, R Pahwa, D Gray, and S Duvvuri. 2023. “Dopamine Agonists in Parkinson’s Disease: Impact of D1-Like or D2-Like Dopamine Receptor Subtype Selectivity and Avenues for Future Treatment. 2023 Jul 7;9:100212. Doi: 10.1016/J.prdoa.2023.100212. ECollection 2023. PMID: 37497384”. Clin Park Relat Disord.

Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's disease. Expert Rev Neurother 2021;21:317-333.

Publication: Journal Article

Jenner, P, A Mori, SD Aradi, and RA Hauser. 2021. “Istradefylline - a First Generation Adenosine A2A antagonist for the Treatment of Parkinson’s Disease. Expert Rev Neurother 2021;21:317-333.”. Expert Rev Neurother.

Get in Touch

Page

Powerful websites to share your science story: from team and research to publications and impact.